These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

69 related items for PubMed ID: 16328069

  • 1. Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer.
    Berrieman HK, Cawkwell L, O'Kane SL, Smith L, Lind MJ.
    Oncol Rep; 2006 Jan; 15(1):283-6. PubMed ID: 16328069
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN, Yu QZ.
    Respiration; 2008 Jan; 75(4):380-5. PubMed ID: 17851225
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study.
    Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, Guttman T, Todor N, Ghilezan N.
    J BUON; 2007 Jan; 12(1):33-9. PubMed ID: 17436399
    [Abstract] [Full Text] [Related]

  • 6. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
    Pan JH, Han JX, Wu JM, Sheng LJ, Huang HN.
    Acta Oncol; 2007 Jan; 46(3):361-6. PubMed ID: 17450472
    [Abstract] [Full Text] [Related]

  • 7. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M, Macha HN, Del Barco S, Cornes P, Vaissière N, Morand M, Riggi M, Abratt R.
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [Abstract] [Full Text] [Related]

  • 8. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
    Sève P, Lai R, Ding K, Winton T, Butts C, Mackey J, Dumontet C, Dabbagh L, Aviel-Ronen S, Seymour L, Whitehead M, Tsao MS, Shepherd FA, Reiman T.
    Clin Cancer Res; 2007 Feb 01; 13(3):994-9. PubMed ID: 17289895
    [Abstract] [Full Text] [Related]

  • 9. Oral versus intravenous administration of vinorelbine as a single agent for the first-line treatment of metastatic nonsmall cell lung carcinoma (NSCLC): A randomized phase II trial.
    Hirsh V, Desjardins P, Needles BM, Rigas JR, Jahanzeb M, Nguyen L, Zembryki D, Leopold LH.
    Am J Clin Oncol; 2007 Jun 01; 30(3):245-51. PubMed ID: 17551300
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL.
    Lung Cancer; 2006 Aug 01; 53(2):171-6. PubMed ID: 16757059
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Stress proteins HSP27 and HSP70i predict survival in non-small cell lung carcinoma.
    Malusecka E, Krzyzowska-Gruca S, Gawrychowski J, Fiszer-Kierzkowska A, Kolosza Z, Krawczyk Z.
    Anticancer Res; 2008 Aug 01; 28(1B):501-6. PubMed ID: 18383892
    [Abstract] [Full Text] [Related]

  • 14. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V, Galetta D, Lorusso V, Caruso M, Verderame F, Pezzella G, Borsellino N, Durini E, Valenza R, Agostara B, Colucci G, Gruppo Oncologico Italia Meridionale.
    Lung Cancer; 2008 Sep 01; 61(3):369-77. PubMed ID: 18308419
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of a biweekly regimen of vinorelbine and cisplatin in advanced non-small cell lung cancer.
    Chen CH, Lin CM, Kao KC, Chang JW, Tsao TC.
    Chang Gung Med J; 2007 Sep 01; 30(3):249-55. PubMed ID: 17760276
    [Abstract] [Full Text] [Related]

  • 16. Fractionated dose of cisplatin (CDDP) and vinorelbine (VNB) chemotherapy for elderly patients with advanced non-small cell lung cancer: phase II trial.
    Buffoni L, Dongiovanni D, Barone C, Fissore C, Ottaviani D, Dongiovanni V, Grillo R, Salvadori A, Birocco N, Schena M, Bertetto O.
    Lung Cancer; 2006 Dec 01; 54(3):353-7. PubMed ID: 17049672
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vinorelbine tartrate: a promising new chemotherapeutic agent.
    Baldwin PD.
    J Intraven Nurs; 1996 Dec 01; 19(1):16-27. PubMed ID: 8708838
    [Abstract] [Full Text] [Related]

  • 19. Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.
    Rossi D, Dennetta D, Ugolini M, Alessandroni P, Catalano V, Fedeli SL, Giordani P, Casadei V, Baldelli AM, Graziano F, Catalano G.
    Clin Lung Cancer; 2008 Sep 01; 9(5):280-4. PubMed ID: 18824450
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.